Lymphoma Roundtable
The panel discussed novel targeted combinations in CNS lymphoma, such as BTK inhibitors in combination with IRAK inhibitors.
The panel, moderated by Grzegorz Nowakowski, MD, discussed how to manage methotrexate toxicity in CNS lymphoma.
The panel, moderated by Grzegorz Nowakowski, MD, also assessed the feasibility of a CSF biomarker for this disease.
Advertisement
Transplantation and radiation are prominent topics in this expert panel segment, moderated by Grzegorz Nowakowski, MD.
The panel, moderated by Grzegorz Nowakowski, MD, discussed options like lenalidomide, BTK inhibitors, and clinical trials.
Grzegorz Nowakowski, MD, asks an expert panel about their approaches and special issues they encounter in first-line care.
Advertisement
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
The panel discusses combination therapy options for patients with DLBCL and FL.
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.